Previous 10 | Next 10 |
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today published its inaugural Environmental, Social, and Governance (ESG) report highlighti...
Axogen reported disappointing fourth quarter results, with procedure volume down 8% on issues related to COVID-19 and hospital staffing. It's credible that the pandemic is impacting results, but Axogen clearly needs to show improved procedure volumes to drive revenue growth. The u...
AxoGen, Inc. (AXGN) Q4 2021 Earnings Conference Call February 22, 2022, 16:30 ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Conference Call Participants David Turkaly - JMP Securities\ Erin Broderick - SVB Leerink P...
AxoGen press release (NASDAQ:AXGN): Q4 Non-GAAP EPS of -$0.08 beats by $0.05. Revenue of $31.53M (-3.0% Y/Y) misses by $0.11M. 2022 revenue will be in the range of $135.0 million to $142.0 million vs. $146.48M consensus. Gross margin is expected to be above 80%. For further details see: ...
ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full yea...
ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in two investor conferences in February. Karen Zader...
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial results on T...
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2021 revenue. Pre...
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings of the Am...
ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has bee...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...